Search

膀胱腫瘍22名でS-TPAをRIA法で測定した.1)未治療患者18名中14名が陽性であった.2)その上昇程度は腫瘍の進展度, 悪性度, 増殖形態, 大きさなどと相関傾向を示した.3)同時測定の尿細胞診, P-CEAの陽性率はおのおの43.8% (7/16), 0%であった.4)治療後のtumor absentの患者4名の値は正常よりやや高値傾向で未治療患者群値との中間であった, Serum tissue polypeptide antigen (S-TPA) levels in 22 patients with bladder cancer were determined using a radioimmunoassay kit by the two-antibody technique to evaluate the usefulness of this parameter as an index of the presence of cancer. As S-TPA values (mean +/- SD) in 72 Japanese normal blood donors (37 male and 35 female) were in the range of 32.4-97.2 units per liter, values higher than 97.2 u/l were considered positive. We found a remarkably increased level of S-TPA in 14 out of 18 (77.8%) patients with untreated cancer and a slightly increased level of S-TPA in 3 out of 4 patients whose tumors had been removed. Elevated S-TPA levels in patients who had tumors remaining were suggested to correlate with histological stage and grade of tumors, type of growth and size of tumors, although not to correlate with number of tumors and whether tumor occurrence was initial or recurrent. Simultaneous urinary cytological examination and measurement of plasma CEA in the same patients gave the positive ratio of 7/16 (43.8%) and 0/14 (0%), respectively. It is possible that S-TPA may be one of the most useful tumor markers in the screening of cancer, diagnosis of histological characteristics, monitoring of cancer therapy and detection of recurrence.

悪性腫瘍患者未治療群20例の血清TPAは, 健康者37例に比して有意に高値を示した.良性疾患患者未治療群との間には, 有意差は認められなかったが, 尿TPAは有意に高値を示した.前立腺癌および膀胱癌患者の多くで血清および尿TPAは治療により低下した.前立腺癌患者では血清TPAとPAP間に有意の相関関係が成立した.良性疾患では尿路感染症をもつ症例は, ない症例に比して血清および尿TPAが上昇した, We measured the serum and urinary TPA in 64 patients with urological cancer, 55 patients with benign urological disease and 37 healthy volunteers. The serum TPA levels in patients with pre-treated cancer were significantly higher than those of healthy volunteers, but showed no significant difference compared to those in patients with a benign urological disease. The urinary TPA levels in patients with pre-treated cancer were significantly higher than those with a benign urological disease, but in some patients with urinary tract infection, very high urinary TPA concentrations were observed. Therefore, the determination of serum and urinary TPA may be useful in detecting urological cancer, but they were not specific tests. On the other hand, as lower serum and urinary TPA levels were observed after treatment of bladder and prostatic cancer, their determinations were considered to be useful in following up patients with these cancers.